AbbVie has successfully renewed its portfolio beyond the patent expiry of Humira, with new drugs Skyrizi and Rinvoq showing strong double-digit revenue growth. Efficient research and development, along with strategic mergers and acquisitions, have built a resilient pipeline supporting profitable growth in the coming years. Although the full-year 2026 earnings per share guidance was lowered to $14.06 due to some short-term expenses, the company's adjusted earnings remain stable. AbbVie offers an attractive price-to-earnings ratio of 14.38 and a steady dividend yield of 3.31%, making it a compelling buy for investors seeking both income and capital appreciation.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
